Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698042 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
A Phase 3 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
- 20
- Study locations
NCT06698042 is a Phase 3 study of Non-Small Cell Lung Cancer and Lung Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 67 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06698042, a Phase 3 study of Non-Small Cell Lung Cancer and Lung Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to learn what happens to pembrolizumab in a person's body over time when it is given as an IV infusion or SC injection.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Pembrolizumab (+) Berahyaluronidase alfa
Study Locations (20)
Guangdong
- The first affiliated hospital, Sun Yat-Sen university ( Site 5011) - Guangzhou
- Southern Medical University Nanfang Hospital ( Site 5003) - Guangzhou
- Huizhou Central People's Hospital ( Site 5004) - Huizhou
- Jiangmen Center Hospital ( Site 5001) - Jiangmen
Fujian
- Fujian Province Cancer Hospital ( Site 5007) - Fuzhou
- The First Affiliated hospital of Xiamen University ( Site 5008) - Xiamen
Sichuan
- West China Hospital of Sichuan University ( Site 5016) - Chengdu
- Sichuan Cancer Hospital. ( Site 5006) - Chengdu
California
- Providence Medical Foundation ( Site 0117) - Fullerton
Illinois
- Illinois Cancer Care ( Site 0101) - Peoria
New York
- Montefiore Medical Center ( Site 0104) - The Bronx
Ohio
- University of Cincinnati Medical Center ( Site 0112) - Cincinnati
Beijing Municipality
- Beijing Peking Union Medical College Hospital ( Site 5000) - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2030-02-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06698042
The ClinicalTrials.gov registry entry for NCT06698042 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06698042 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Guangdong, Fujian, Sichuan.
Frequently Asked Questions
What is clinical trial NCT06698042 about?
NCT06698042 is a clinical study titled "A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)". Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV...
What is the current status of trial NCT06698042?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2024-11-21. Estimated completion is 2030-02-11.
What conditions does trial NCT06698042 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer.
What interventions are being tested in trial NCT06698042?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Pembrolizumab (+) Berahyaluronidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT06698042?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06698042 being conducted?
This trial has 20 study locations across California, Illinois, New York, Ohio, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.